Please assess the completion status of the following clinical trial:

Trial Title: Optimisation of Antipsychotic Drug Use in Older People

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Treatment and Control (antipsychotic free) Group~Schizophrenia~* meet diagnostic criteria for schizophrenia-like illness~* aged between 60 and 95 years of age~* score \<6 on the Geriatric depression scale~Alzheimer's~* meet diagnostic criteria for AD~* score \<=4 on the Modified Hachinski Ischaemia Scale~* score \< 8 on a modified version of the UPDRS~* aged between 60 and 95 years of age~* score \<6 on the Geriatric depression scale~Exclusion Criteria~Treatment Group~Schizophrenia~* current or past history of addiction, traumatic brain injury or epilepsy~* prescribed any drug that interferes with brain dopamine in past 2 weeks (6 weeks if depot antipsychotic medication).~* medical conditions that might affect Ability to tolerate a brain scan~* unable to give informed consent~Alzheimer's~* current or past history of psychiatric illness, traumatic brain injury or epilepsy~* prescribed an antipsychotic or other oral drug that interferes with brain dopamine function within the past 2 weeks (6 weeks if depot antipsychotic medication).~* medical conditions that might affect a person's ability to tolerate a brain scan~Control (antipsychotic free) Group~Schizophrenia~* Prescribed psychotropic medication~* unable to give informed consent~Alzheimer's~• Prescribed psychotropic medication

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Patients - dose titration (Type: EXPERIMENTAL): Amisulpride 50-200mg, 4-12 weeks, with brain imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).